RBPMS2

Across TCGA pan-cancer cohorts, RBPMS2 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of RBPMS2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where RBPMS2 RNA is repressed in tumor relative to normal tissue. In most cancer types RBPMS2 is over-expressed in tumor, although a few such as BLCA and COAD show the opposite, repressed pattern.

BLCA, COAD, and THCA are the cancer types where RBPMS2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RBPMS2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	−4.692	<.001	11	view →
COAD	Male	All	−2.692	<.001	10	view →
THCA	Male	III,IV	−1.777	<.001	9	view →
LIHC	Female	III,IV	+1.531	<.001	9	view →
KIRP	Male	All	−1.547	<.001	8	view →
STAD	Female	All	−3.332	<.001	7	view →
LUSC	Female	II,III,IV	−1.294	<.001	7	view →
BRCA	All	All	−1.306	<.001	6	view →
READ	All	All	−3.072	<.001	5	view →
KIRC	Male	All	−0.464	.001	4	view →
UCEC	All	All	−1.626	<.001	2	view →
PRAD	All	All	−0.945	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

RBPMS2–BLCA

Open the BLCA breakdown →